On Friday, Shares of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 0.73% to $130.52. The stock traded total volume of 2,874 shares lower than the average volume of 635.89K shares.
Jazz Pharmaceuticals plc (JAZZ) recently declared financial results for the full year and the fourth quarter of 2018.
GAAP net income for 2018 was $447.10M, or $7.30 per diluted share, contrast to $487.80M, or $7.96 per diluted share, for 2017. GAAP net income for the fourth quarter of 2018 was $159.50M, or $2.64 per diluted share, contrast to $232.20M, or $3.79 per diluted share, for the fourth quarter of 2017. 2017 GAAP net income, for the full year and the fourth quarter, included a net tax benefit of $148.80M, or $2.43 per diluted share, related to enactment of the U.S. Tax Cuts and Jobs Act (U.S. Tax Act).
Adjusted net income for 2018 was $838.60M, or $13.70 per diluted share, contrast to $676.70M, or $11.04 per diluted share, for 2017. Adjusted net income for the fourth quarter of 2018 was $220.00M, or $3.64 per diluted share, contrast to $180.50M, or $2.95 per diluted share, for the fourth quarter of 2017.
Cash Flow and Balance Sheet
As of December 31, 2018, cash, cash equivalents and investments were $824.60M and the outstanding principal balance of the company’s long-term debt was $1.80B. In 2018, the company generated $798.90M of cash from operations, received a $50.00M upfront payment for the sale of rights to Prialt, purchased a priority review voucher for $110.00M and used $523.70M to repurchase shares.
In 2018, the company repurchased about 3,530.0K ordinary shares under the company’s share repurchase program at an average cost of $148.33 per ordinary share. In November and December 2018, the company’s board of directors increased the existing share repurchase program by $320.00M and $400.00M, respectively. As of December 31, 2018, the remaining amount authorized for share repurchases was $379.10M.
JAZZ has the market capitalization of $7.25B and its EPS growth ratio for the past five years was 15.80%. The return on assets ratio of the Company was 8.40% while its return on investment ratio stands at 12.20%. Price to sales ratio was 3.84 while 96.10% of the stock was owned by institutional investors.
